{"nctId":"NCT02132117","briefTitle":"Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea","startDateStruct":{"date":"2014-06"},"conditions":["Erythema","Rosacea"],"count":445,"armGroups":[{"label":"Oxymetazoline HCL Cream 1.0%","type":"EXPERIMENTAL","interventionNames":["Drug: Oxymetazoline HCL Cream 1.0%"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle to Oxymetazoline HCL Cream"]}],"interventions":[{"name":"Oxymetazoline HCL Cream 1.0%","otherNames":[]},{"name":"Vehicle to Oxymetazoline HCL Cream","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Moderate to severe persistent facial erythema associated with rosacea.\n\nExclusion Criteria:\n\n* Greater than 3 inflammatory lesions on the face\n* Current treatment with monoamine oxidase (MAO) inhibitors\n* Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales","description":"The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29. Baseline was defined as the measurement at pre-dose on Day 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29","description":"The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29","description":"DIA of photographs was used to assess rosacea facial redness and was defined as percentage of facial area occupied by redness. A higher value in the percentage of facial area occupied by facial redness indicated more redness. A negative/ lower number percent change from Baseline indicates improvement.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.70","spread":"144.776"},{"groupId":"OG001","value":"0.00","spread":"225.452"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.95","spread":"170.735"},{"groupId":"OG001","value":"2.25","spread":"198.138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.95","spread":"131.933"},{"groupId":"OG001","value":"5.15","spread":"200.530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.60","spread":"145.898"},{"groupId":"OG001","value":"1.00","spread":"195.291"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29","description":"Participants assessed their treatment satisfaction by answering Item #9 of the SAT-RFR: \"Right now, how satisfied are you with the effect your study medication had on your facial redness?\" using a 5-point scale where 0= very dissatisfied, 1=dissatisfied, 2=neither satisfied or dissatisfied, 3=satisfied, or 4=very satisfied. The percentage of participants who answered Satisfied or Very Satisfied is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","spread":null},{"groupId":"OG001","value":"34.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"32.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29","description":"Participants assessed the burning sensation associated with rosacea facial redness by answering Item #4 of the SA-RFR: \"Right now, how much does your face burn because of your facial redness?\" using a 5-point scale where 0=less severe to 4=severe. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.97"},{"groupId":"OG001","value":"-1.6","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.93"},{"groupId":"OG001","value":"-1.6","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.91"},{"groupId":"OG001","value":"-1.7","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.92"},{"groupId":"OG001","value":"-1.7","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1","description":"The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null},{"groupId":"OG001","value":"16.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":223},"commonTop":[]}}}